The Pulse of the MedTech Industry Report 2024 from EY is now available for download! While research shows that the MedTech industry is still growing, it is increasingly walking a narrow path between converging top-line and bottom-line pressures. With deep insights from EY thought leaders and perspectives from top MedTech executives on the current financing environment, capital efficiency viewpoints, what’s next in MedTech financing, and the future of innovation, the EY analysis on the state of the industry leaves no stone unturned.
Click here for details: www.ey.com/pulse
Related Reading
Blog / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Tariffs
Medtech is Essential: Industry Supports Call for Tariff Flexibility
May 29, 2025
AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
URGENT: Court Ruling on Tariffs — Implications for Medtech
Now On Demand!
Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!
News / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Tariffs
Swiss Medtech and AdvaMed Call for Zero for Zero Tariffs and Recognition of FDA Approvals and Clearances
May 20, 2025
Bern/Washington – Swiss Medtech, the leading trade association for medical technology companies in Switzerland, and AdvaMed, the U.S. Medtech Association and the world’s largest organization representing medtech innovators, are jointly calling for reciprocal “zero for zero” tariffs between the two countries.
News / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Tariffs
AdvaMed Testifies in U.S. Senate
May 14, 2025
WASHINGTON – Today, President and CEO Scott Whitaker of AdvaMed, the Medtech Association, testified before the U.S. Senate Committee on Finance in its hearing focused on the impact of tariffs on U.S. supply chains. AdvaMed was the only health care organization invited to discuss the medical technology supply chain.
News / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed, U.K. Medtech Association Call for Flexibility on Tariffs, “Regulatory Convergence”
May 6, 2025
WASHINGTON—AdvaMed, the Medtech Association, the world’s largest organization representing medtech innovators, and the Association of British HealthTech Industries (ABHI), the leading trade association for medical technology companies in the United Kingdom, are calling for reciprocal “zero for zero” tariffs between the two countries and greater regulatory convergence, noting the prominence of medtech in both the U.S. and U.K. health care systems and economies and the critical need to avoid disruptions in patient care that tariffs could cause in both countries.
Event / Global & Trade / Tariffs
MedTech in Flux: Navigating Global Disruption
May 22, 2025
10:00 AM – 11:00 AM
Join IQVIA MedTech for a high-impact webinar: “MedTech in Flux: Navigating Global Disruption” to unpack the consequences of today’s trade environment and share how leaders are mitigating risk and driving innovation amid instability.
Blog / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Why Lifesaving Medtech Should Be Tariff-free: An Interview with AdvaMed’s CEO
April 30, 2025
AdvaMed President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential, lifesaving medtech products.
News / China / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners
April 25, 2025
WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech.